

# Pilot Evaluation Of A Clinical Xeno Heart Transplant Regimen In A Preclinical Model

I. Illeka<sup>1</sup>, R. Chaban<sup>1</sup>, K. Kinoshita<sup>1</sup>, G. McGrath<sup>1</sup>, Z. Habibabady<sup>1</sup>, A. Calhoun<sup>1</sup>, A. Maenaka<sup>1</sup>, M. Ma<sup>1</sup>, V. Diaz<sup>1</sup>, S. Sanatkar<sup>1</sup>, S. Low<sup>2</sup>, W. Qin<sup>2</sup>, K. Hall<sup>2</sup>, K. Whitworth<sup>3</sup>, D.K.C. Cooper<sup>1</sup> R.N. Pierson III<sup>1</sup>

<sup>1</sup>Center for Transplantation Sciences, Massachusetts General Hospital and Harvard Medical School, Boston, MA

<sup>2</sup>eGenesis, Inc., Cambridge, MA

<sup>3</sup>National Swine Resource and Research Center (NSRRC), Columbia, MO

# Relevant Disclosures

- *R. Chaban was supported by the Benjamin Research Fellowship from the German Research Foundation (DFG)*
- *I. Illeka is supported by T32 5T32 AI007529-24*
- *Gene edited pigs were provided by eGenesis and NSRRC (NIH grant U42OD011140)*
- *Tonix Pharmaceuticals provided TNX-1500\*, a humanized, Fc-modified, dimeric anti-CD154 mAb*
- *This work was supported by NIH grants UO1 AI153612 (Pierson), U19 AI090959 (Cooper), and sponsored research agreements with Tonix Pharmaceuticals and eGenesis*
- *D.K.C. Cooper is a consultant to eGenesis*



\* TNX-1500 is an investigational new biologics and is not approved for any indication



CENTER FOR  
TRANSPLANTATION SCIENCES

# Background

- Gene-edited (GE) pigs for Xenotransplantation.
  - Remove CHO antigen targets of preformed Ab
    - TKO (Gal-1,3- $\alpha$ Gal, Neu5Gc, Sd )
  - Add human regulatory molecules
    - Complement: CD46, CD55, CD59
    - Coagulation: TBM, EPCR, TFPI
  - Add anti-inflammatory ‘transgenes’
    - CD47, HLA-E/ $\beta$ 2, HO-1, A20, CD39

# Background




- We evaluated hearts from multi-GE pigs in baboon transplants treated with a novel costimulation-based immunosuppressive regimen and cold-perfused ‘ischemia minimization’.

# Methods

- Pig Donors
  - 3-, 11-, or 15-GE pig hearts
  - novel costimulation-based immunosuppressive regimen
  - cold-perfused storage technique designed to minimize graft ischemia.
- Five baboons' recipients received heterotopic heart transplants using Steen's cold-perfusion ischemia minimization
  - 3 Reference pig hearts (Ntl. Swine Resource & Research Ctr: NSRRC)
    - 3-GE pigs: GTKO.β4GALNT2KO.CD55
  - 2 Multi-GE pig hearts (eGenesis) (TKO = GTKO.CMAHKO.β4GALNT2KO)
    - TKO.hCD46.CD55.TBM.TFPI.HLAE/β2M.CD47.CD59.CD39.A20.HO1.PD-1 (**EGEN-4737[15-GE]**)
    - TKO.hCD46.CD55.TBM.TFPI.HLAE/β2M.CD47.EPCR (**EGEN-4417[11-GE]**)

# Methods: Heterotopic Heart Transplantation

- Standard UW cold perfusate.
- Ischemia minimization: Steen method
  - battery-powered portable perfusion circuit
  - 4°C Steen Solution
  - Protocol 2-hr perfusion
- Heterotopic abdominal xenograft transplant



# Methods: Steen Ischemia Minimization

- Steen: buffered extracellular solution (laboratory-made)
- 240ml of washed human RBCs; 760 ml Steen solution
- Aortic perfusion at 4°C, 40-50 mmHg, immersed in reservoir; LV vent


# Methods: Recipient Immunosuppressive Treatment Regimen

- Induction Therapy
  - Antithymocyte Globulin (ATG)
  - $\alpha$ CD20
- Day of Surgery Therapy
  - Thromboxane inhibitor (BIA)
  - TNF Inhibitor (Etanercept)
  - Interleukin 6 inhibitor receptor blocker (Tocilizumab)
- Maintenance Therapy
  - $\alpha$ CD154 (TNX-1500), Mycophenolate Mofetil(MMF), Corticosteroids
  - Interleukin 6 inhibitor receptor blocker (Tocilizumab)


# Results: Summary

Animal ID	GE	Anticoagulation	Major complication	Graft Survival (Days)	Final Biopsy
B3022	3G	Heparin IV	Graft rupture	3	Antibody mediated rejection
B2922	3G	Heparin IV	Graft rupture	5	Antibody mediated rejection
B8522	3G	Heparin IV	Refractory Ventricular fibrillation	0	No evidence of rejection
B2521	EGEN-4737 (15G)	None	Abdominal dehiscence	20	Antibody mediated rejection
B2621	EGEN-4417 (11G)	None	None	300	Acute cellular rejection (3R) with severe antibody mediated rejection

# Results : Graft Survival and Function




# Results: Cardiac Echo, 11-GE Pig







MASSACHUSETTS  
GENERAL HOSPITAL

CENTER FOR  
TRANSPLANTATION SCIENCES

# Results: Anti-pig Antibody in 3-GE pigs



# Results: Anti-pig Antibody in multi-GE pigs




# Results: Histology

H&E


H&E

C4d/C4d/H&E


A B3022 (3GE) D#3




B B8522 (3GE) D#0




C B8522 (3GE) D# 0




D B2521 (15GE) D# 20




E B2521 (15GE) D# 20




F B2521 (15GE) D# 20




G B2621 (11GE) D# 50



H B2621 (11GE) D# 110



I B2621 (11GE) D# 300



# Conclusion

- This pilot experience with multi-GE porcine hearts in the context of a clinically applicable ischemia minimization and immunosuppressive regimen supports our working hypothesis that is effective to prolong heart xenograft survival.
- We plan to further test this hypothesis in an orthotopic heart xenograft model.

# Thank you!

## Key Contributors:

R Chaban

A Calhoun

V Diaz

I Ileka

RN Pierson III

